Header Logo

Connection

AARON THRIFT to Adenocarcinoma

Back to Details
This is a "connection" page, showing publications AARON THRIFT has written about Adenocarcinoma.
AARON THRIFT
Connection Strength
13.162
Adenocarcinoma
  1. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2026 Jan; 36(1):49-68.
    View in: PubMed
    Score: 0.575
  2. Somatic mutations of esophageal adenocarcinoma: a comparison between Black and White patients. Sci Rep. 2024 04 18; 14(1):8988.
    View in: PubMed
    Score: 0.518
  3. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.455
  4. Sociodemographic and Facility-Related Disparities in the Delivery of Guideline-Concordant Therapy Among Patients With Esophageal Adenocarcinoma. JCO Oncol Pract. 2022 07; 18(7):e1181-e1197.
    View in: PubMed
    Score: 0.451
  5. Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most. Am J Gastroenterol. 2022 07 01; 117(7):1056-1062.
    View in: PubMed
    Score: 0.451
  6. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):1-26.
    View in: PubMed
    Score: 0.407
  7. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies? Dig Dis Sci. 2021 06; 66(6):1965-1973.
    View in: PubMed
    Score: 0.399
  8. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.395
  9. Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence: Reply From Authors. Am J Gastroenterol. 2018 11; 113(11):1724-1725.
    View in: PubMed
    Score: 0.354
  10. Editorial: less acid, less cancer? Is this the question? Authors' reply. Aliment Pharmacol Ther. 2018 10; 48(8):878-879.
    View in: PubMed
    Score: 0.353
  11. Time to Tailor Surveillance Intervals of Nondysplastic Barrett's Esophagus According to Segment Length and Persistence Over Multiple Endoscopies. Clin Gastroenterol Hepatol. 2019 04; 17(5):832-834.
    View in: PubMed
    Score: 0.352
  12. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.349
  13. Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? Dig Dis Sci. 2018 Aug; 63(8):1988-1996.
    View in: PubMed
    Score: 0.349
  14. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.348
  15. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.346
  16. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.346
  17. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.345
  18. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2018 10; 16(10):1598-1606.e4.
    View in: PubMed
    Score: 0.339
  19. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic?Variants. Gastroenterology. 2018 04; 154(5):1273-1281.e3.
    View in: PubMed
    Score: 0.334
  20. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.316
  21. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Gastroenterol. 2016 07; 32(4):319-24.
    View in: PubMed
    Score: 0.302
  22. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016 Apr; 41:88-95.
    View in: PubMed
    Score: 0.293
  23. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
    View in: PubMed
    Score: 0.288
  24. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2225-32.
    View in: PubMed
    Score: 0.277
  25. Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus. Best Pract Res Clin Gastroenterol. 2015 Feb; 29(1):41-50.
    View in: PubMed
    Score: 0.270
  26. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.267
  27. Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. Clin Gastroenterol Hepatol. 2014 Oct; 12(10):1667-76.e1.
    View in: PubMed
    Score: 0.256
  28. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):138-44.e2.
    View in: PubMed
    Score: 0.234
  29. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012 Dec; 23(12):3155-3162.
    View in: PubMed
    Score: 0.230
  30. The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer. 2012 Sep 01; 131(5):E759-68.
    View in: PubMed
    Score: 0.223
  31. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control. 2012 Apr; 23(4):555-64.
    View in: PubMed
    Score: 0.223
  32. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.139
  33. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia. Gastroenterology. 2024 06; 166(6):1020-1055.
    View in: PubMed
    Score: 0.131
  34. Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma. Minerva Gastroenterol (Torino). 2024 Dec; 70(4):454-462.
    View in: PubMed
    Score: 0.130
  35. GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut. 2023 04; 72(4):612-623.
    View in: PubMed
    Score: 0.115
  36. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022 09; 163(3):649-658.e2.
    View in: PubMed
    Score: 0.114
  37. International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. Am J Gastroenterol. 2021 05 01; 116(5):1072-1076.
    View in: PubMed
    Score: 0.105
  38. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.105
  39. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2020 12; 159(6):2065-2076.e1.
    View in: PubMed
    Score: 0.101
  40. Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study. Dig Dis Sci. 2020 10; 65(10):2992-2999.
    View in: PubMed
    Score: 0.096
  41. Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):427-433.
    View in: PubMed
    Score: 0.095
  42. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2020 11; 18(12):2701-2709.e3.
    View in: PubMed
    Score: 0.095
  43. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.095
  44. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer. 2019 12 01; 125(23):4210-4223.
    View in: PubMed
    Score: 0.094
  45. Risk and Predictors of Esophageal and Stomach Cancers in HIV-Infected Veterans: A Matched Cohort Study. J Acquir Immune Defic Syndr. 2019 07 01; 81(3):e65-e72.
    View in: PubMed
    Score: 0.093
  46. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia. Aliment Pharmacol Ther. 2019 05; 49(10):1274-1281.
    View in: PubMed
    Score: 0.091
  47. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clin Gastroenterol Hepatol. 2019 10; 17(11):2227-2235.e1.
    View in: PubMed
    Score: 0.090
  48. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.089
  49. Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology. 2019 01; 156(1):43-45.
    View in: PubMed
    Score: 0.088
  50. Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clin Gastroenterol Hepatol. 2019 02; 17(3):560-562.e2.
    View in: PubMed
    Score: 0.086
  51. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018 08; 155(2):316-326.e6.
    View in: PubMed
    Score: 0.085
  52. Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2018 08; 16(8):1229-1236.e4.
    View in: PubMed
    Score: 0.085
  53. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.079
  54. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.076
  55. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2017 10; 66(10):1739-1747.
    View in: PubMed
    Score: 0.076
  56. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.075
  57. Can we really predict risk of cancer? Cancer Epidemiol. 2013 Aug; 37(4):349-52.
    View in: PubMed
    Score: 0.061
  58. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.